Clinical trials · Kansas City, MO
Heart failure clinical trials in Kansas City
We’re tracking 29 recruiting heart failure studies with a site in or near Kansas City — including Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Kansas City
- NCT07037459RecruitingPhase 3
A study of a new drug for heart failure with obesity
This trial tests a medication called maridebart cafraglutide for people with heart failure (where the heart doesn't pump as well as it should) and obesity. The goal is to see if it can help improve symptoms and outcomes.
Kansas City, MissouriAges 18–99 - NCT07192952RecruitingPhase 3
Long-term safety of finerenone in children and young adults with heart failure
This study tests the long-term safety of the drug finerenone when taken alongside standard heart failure treatments in children and young adults with weakened heart pumping function (left ventricular systolic dysfunction). It includes both children already in a related study and new infants under 6 months old.
Kansas City, MissouriAges Up to 18 years - NCT06736574RecruitingPhase 3
Study of omecamtiv mecarbil for chronic heart failure with very weak heart pump
This study tests an investigational medicine (omecamtiv mecarbil) for people with chronic heart failure and very low pumping strength. It looks at whether the drug can help prevent heart failure events or the need for stronger treatments.
Kansas City, MissouriAges 18–85 - NCT05180773RecruitingPhase 4
Bromocriptine for new postpartum heart weakness
This trial studies whether bromocriptine improves health outcomes in people recently diagnosed with peripartum cardiomyopathy (a weakened heart during late pregnancy or soon after delivery). You may be asked about timing after childbirth, heart strength tests, and whether you plan to keep breastfeeding.
Kansas City, MissouriAges 18 years+ - NCT07188805RecruitingPhase 3
Finerenone for children with heart failure
This study tests a new medicine called finerenone (a pill) to see if it helps children with heart failure who have a weak pumping heart. It compares finerenone to a placebo (a pill with no medicine) while both groups continue their usual heart treatments.
Kansas City, MissouriAges 6 months–17 years - NCT05934487Recruiting
Monitoring device trial for stable heart failure symptoms
This trial tests whether a wearable home monitoring system (myCordella™) can help people with moderate heart failure (NYHA class II or III) by tracking heart pressure and supporting follow-up care. It may help detect changes earlier so clinicians can adjust treatment sooner.
Kansas City, MissouriAges 18 years+ - NCT07112924Recruiting
CCM Heart Device Registry Study
This registry study follows patients who have or will get a CCM device to see how well it works and how safe it is over time. It helps doctors learn more about improving heart function in people with heart failure.
Kansas City, MissouriAges 18 years+ - NCT06935370RecruitingPhase 3
Testing vicadrostat with empagliflozin for heart failure with weak pump
This trial tests a new drug called vicadrostat combined with another drug, empagliflozin, for people with heart failure and a weak heart pump. It aims to see if this combination helps improve symptoms and outcomes.
Kansas City, MissouriAges 18 years+ - NCT06024746RecruitingPhase 3
Finerenone plus SGLT2i for hospitalized heart failure
This trial tests whether adding two heart medicines together (finerenone and an SGLT2 inhibitor) helps people who are in the hospital for heart failure recover better. It may be an option for you if you are currently hospitalized and your heart stress markers are high.
Kansas City, MissouriAges 18 years+ - NCT07207811RecruitingPhase 3
Coramitug for heart failure caused by ATTR amyloidosis
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
Kansas City, MissouriAges 18 years+ - NCT06425848Recruiting
Heart failure monitoring study
This study looks at how a small monitor inside the blood vessel to the lungs helps manage heart failure. It aims to improve care for people with advanced heart failure.
Kansas City, MissouriAges 18–100 - NCT06526195Recruiting
A study of CardioMEMS and HeartMate 3 for advanced heart failure
This trial tests if a combination of a tiny lung-artery pressure sensor (CardioMEMS) and a mechanical heart pump (HeartMate 3) is safe and effective for people with advanced heart failure. If you qualify, you'll either get the heart pump plus standard medical therapy, or continue with standard therapy alone and have your pressure monitored remotely.
Kansas City, MissouriAges 18 years+ - NCT00271180Recruiting
Tracks long-term performance of Medtronic heart devices
This study follows how well certain Medtronic heart devices work over the long term. You may be included if you have a qualifying Medtronic implant and the research team can reliably get your implant and follow-up information.
Kansas City, MissouriAges Any age - NCT05388097Recruiting
Quality program to reduce hospital readmissions for heart failure
This trial tests whether a new hospital “quality improvement” program can lower the chances of coming back to the hospital after being admitted for acute heart failure. It focuses on social needs (like resources and support) that can affect recovery and readmissions.
Kansas City, MissouriAges 18–99 - NCT04278404Recruiting
Drug safety study for children already on certain medicines
This study measures how certain medicines move through the body and checks their safety in children. It may help doctors better understand dosing and side effects in kids who are already receiving these treatments, or in some kids who recently tested positive for COVID-19.
Kansas City, MissouriAges birth–20 years - NCT06424288RecruitingPhase 3
Testing vicadrostat plus empagliflozin for heart failure
This study tests whether adding a new study drug called vicadrostat to the standard heart failure medicine empagliflozin helps people with heart failure. It may be a good option if you have heart failure with preserved pumping function and are not already on a medicine called an MRA.
Kansas City, MissouriAges 18 years+ - NCT06677060RecruitingPhase 3
Study of baxdrostat plus dapagliflozin for heart risk in type 2 diabetes
This study tests whether a new drug called baxdrostat, when added to the diabetes medicine dapagliflozin (Farxiga), can prevent heart failure and heart-related death in people with type 2 diabetes, high blood pressure, and existing heart or blood vessel disease. You may be able to join if you have type 2 diabetes, heart or blood vessel disease, high blood pressure, and at least one extra risk factor for heart failure.
Kansas City, MissouriAges 40 years+ - NCT07567001RecruitingPhase 3
Testing NNC0487-0111 for Heart Failure and Obesity
This study tests whether a new medication called NNC0487-0111 can help people with heart failure who also have obesity. Researchers will compare it to a placebo (inactive pill) to see if it improves heart function and overall health.
Kansas City, MissouriAges 18 years+ - NCT06307652RecruitingPhase 3
Testing a new heart failure and kidney treatment combo
This study tests a new combination of two medicines (balcinrenone and dapagliflozin) for people with heart failure and reduced kidney function. The goal is to see if this combination helps improve heart and kidney health better than current treatments.
Kansas City, MissouriAges 18–130 - NCT06678841Recruiting
Pacing therapy for heart failure with preserved pumping ability
This study tests a new pacing approach for people with a specific type of heart failure (HFpEF) to see if it can improve symptoms and quality of life. It involves a pacemaker-like device that adjusts heart rate based on your needs.
Kansas City, MissouriAges 40 years+ - NCT06008197RecruitingPhase 3
A study of finerenone for hospitalized heart failure patients
This trial tests a medication called finerenone to see if it helps people hospitalized for heart failure live longer and have fewer heart-related problems. It may be an option for those with a certain type of heart failure where the heart's pumping strength is mildly reduced or normal.
Kansas City, MissouriAges 18 years+ - NCT06033950RecruitingPhase 3
A study of finerenone for heart failure patients who can't take standard MRA drugs
This study tests whether finerenone, a new type of drug, can help people with heart failure who cannot take standard steroid-based MRAs (a kind of heart medication) because of side effects or other reasons. It aims to see if it improves symptoms and is safe for you.
Kansas City, MissouriAges 18 years+ - NCT05064709Recruiting
Test device for heart failure symptoms in some patients
This study tests whether a heart-related device called CCM can improve symptoms and daily function in people with heart failure and a moderately reduced pumping strength. It may help if you’ve had recent heart-failure-related hospital care or urgent treatment and your heart and overall health fit the study limits.
Kansas City, MissouriAges 18 years+ - NCT06310031Recruiting
Testing BrioVAD heart pump for severe heart failure
This trial tests a new left-ventricular assist device (LVAD) called BrioVAD for people with advanced heart failure who are not getting enough benefit from medicines. If you qualify, the device is implanted to help your heart pump blood.
Kansas City, KansasAges 18–100
Hear when a new Heart failure trial opens near Kansas City, MO
We’ll email you when one opens near Kansas City, MO — at most once a week, no account needed, unsubscribe anytime.
Heart failure trials in other cities
Where these studies are running near Kansas City
Institutions with a site for the recruiting heart failure studies listed above.
- Saint Luke's Hospital of Kansas City · 10 studies
- University of Kansas Medical Center · 10 studies
- Children's Mercy Kansas City · 3 studies
- Kansas City VA Medical Center · 2 studies
- Research Site · 2 studies
- AHMG Cardiology and Surgery
- Clinical Research Consultants
- CON-10002 Kansas City, MO Investigative Site
What taking part in a heart failure study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting heart failure studies in Missouri.
Common questions
- Are there heart failure clinical trials near Kansas City?
- Yes. We're currently tracking 29 recruiting heart failure studies with a site near Kansas City, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a heart failure study near Kansas City?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Kansas City to take part?
- Not necessarily. These studies have a site near Kansas City, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a heart failure trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New heart failure studies open near Kansas City regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.